Literature DB >> 1320526

Clinical effects and mechanism of action of sumatriptan in migraine.

M D Ferrari1, P R Saxena.   

Abstract

Sumatriptan is a novel, highly effective drug against migraine and cluster headache attacks. It shows a remarkably selective pharmacological profile in animals. Determination of its mechanism of action in human should further the understanding of the pathophysiology of migraine and cluster headache. We, therefore, review current knowledge on the clinical and pharmacological effects of sumatriptan. Important pharmacological actions of sumatriptan are (i) poor penetration of the blood-brain barrier suggesting a peripheral point of action; (ii) 5-HT1-like/5-HT1d receptor-mediated vasoconstriction of large cerebral arteries and dural vessels; and (iii) blockade of neurogenic dural inflammation via 5-HT1d autoreceptor-mediated inhibition of vasoactive neuropeptides within the trigeminovascular system. Future research will tell which mechanism is involved in the pathophysiology of migraine and cluster headache.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320526     DOI: 10.1016/0303-8467(92)90028-2

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  7 in total

Review 1.  Safety of sumatriptan in pregnancy: a review of the data so far.

Authors:  Elizabeth Loder
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.

Authors:  Chaouki K Khoury; James R Couch
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

Review 3.  Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache.

Authors:  G L Plosker; D McTavish
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

4.  A Comparative Study of Orally Delivered PBCA and ApoE Coupled BSA Nanoparticles for Brain Targeting of Sumatriptan Succinate in Therapeutic Management of Migraine.

Authors:  Priti Girotra; Shailendra Kumar Singh
Journal:  Pharm Res       Date:  2016-03-22       Impact factor: 4.200

5.  Study of effect of nimodipine and acetaminophen on postictal symptoms in depressed patients after electroconvulsive therapy (SYNAPSE).

Authors:  Joey P A J Verdijk; Julia C M Pottkämper; Esmée Verwijk; Guido A van Wingen; Michel J A M van Putten; Jeannette Hofmeijer; Jeroen A van Waarde
Journal:  Trials       Date:  2022-04-18       Impact factor: 2.728

6.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

7.  ACE gene dosage determines additional autonomic dysfunction and increases renal angiotensin II levels in diabetic mice.

Authors:  Oscar Albuquerque de Moraes; Karin Flues; Kátia Bilhar Scapini; Cristiano Mostarda; Fabiana de Sant'Anna Evangelista; Bruno Rodrigues; Daniela Ravizzoni Dartora; Patricia Fiorino; Kátia De Angelis; Maria Cláudia Irigoyen
Journal:  Clinics (Sao Paulo)       Date:  2018-08-02       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.